Skip to content

US · NYXH · MEDICAL - SPECIALTIES

Nyxoah S.A. (NYXH) intrinsic value and stock valuation

$0.81as of 2026-11-21 · Mkt cap 55.85M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nyxoah S.A. DCF and intrinsic value

InvestorsCraft values NYXH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NYXH’s statements →

Nyxoah S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Specialties Mont-Saint-Guibert, WA 1435 nyxoah.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$10M+169.9% 5y CAGRd
20172025
Net income
-$-90.08M
20172025
Free cash flow
-$-68.3M
20172025
Total equity
$49.1M-16.2% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$10M$4.52M$4.35M$3.08M$850K
Operating income-$-82.94M-$-58.81M-$-45.1M-$-32.5M-$-26.24M
Net income-$-90.08M-$-59.24M-$-43.21M-$-31.23M-$-27.62M
EPSd-$-2.36M-$-1.81M-$-1.54M-$-1.21M-$-1.16M
Operating cash flow-$-67.5M-$-49.23M-$-44.78M-$-28.76M-$-25.34M
Capital expenditure-$-800K-$-6.07M-$-10.96M-$-16.35M-$-11.82M
Free cash flow-$-68.3M-$-55.3M-$-55.74M-$-45.1M-$-37.15M
Total assets$118.4M$158.4M$124.2M$146.1M$170.8M
Total debt$42.1M$22.7M$12.7M$11.9M$11.7M
Net debt$12.1M-$-11.53M-$-8.91M-$-6.01M-$-123.83M
Total equity$49.1M$113.3M$98M$120.3M$148.6M
Cash and short-term investments$48M$85.6M$57.8M$94.9M$135.5M
Income statement
20252024202320222021
Revenue$10M$4.52M$4.35M$3.08M$850K
Cost of revenue$3.69M$1.55M$1.66M$1.15M$300K
Gross profit$6.33M$2.97M$2.69M$1.93M$550K
Research and development expenses$42.8M$34.3M$27.7M$15.9M$5.95M
Selling, general and administrative expenses$46.4M$28.5M$20.6M$18.9M$11.1M
Other expenses$10K-$-1.01M-$-510K-$-280K$9.73M
Operating expenses$89.3M$61.8M$47.8M$34.4M$26.8M
Cost and expenses$93M$63.3M$49.5M$35.6M$27.1M
Interest income$1.83M$2.5M$2.57M$370K$0.00
Interest expense$1.69M$1.9M$1.21M$240K$390K
Depreciation and amortization$4.48M$760K$2.36M$1.93M$1.66M
Ebitda-$-82.9M-$-53.77M-$-42.08M-$-27.89M-$-22.59M
Operating income-$-82.94M-$-58.81M-$-45.1M-$-32.5M-$-26.24M
Total other income/expenses, net-$-6.13M$2.38M$450K$2.44M$1.6M
Income before tax-$-89.08M-$-56.43M-$-44.66M-$-30.06M-$-24.64M
Income tax expense$1.01M$2.8M-$-1.45M$1.17M$2.98M
Net income-$-90.08M-$-59.24M-$-43.21M-$-31.23M-$-27.62M
Weighted average shares outstanding$38.1M$32.7M$28M$25.8M$23.8M
Weighted average diluted shares outstanding$38.1M$32.7M$28M$25.8M$23.8M
Balance sheet
20252024202320222021
Cash and short-term investments$48M$85.6M$57.8M$94.9M$135.5M
Net receivables$7.72M$6.16M$5.63M$2.23M$2.51M
Inventory$4.66M$4.72M$3.31M$880K$350K
Total current assets$61.2M$98.1M$68.4M$100.3M$140.1M
Property, plant and equipment, net$5.34M$8.25M$7.98M$5.62M$5.24M
Goodwill and intangible assets$50.1M$50.4M$46.6M$40M$25.3M
Long-term investments$1.72M$0.00$0.00$170K$160K
Total non-current assets$57.2M$60.3M$55.8M$45.8M$30.8M
Total assets$118.4M$158.4M$124.2M$146.1M$170.8M
Accounts payable$13.7M$3.75M$4.1M$1.87M$2.39M
Short-term debt$23.8M$1.37M$1.22M$1.11M$1.14M
Deferred revenue$890K$120K$0.00$0.00$0.00
Total current liabilities$48.9M$21.5M$14.4M$14.9M$11.6M
Long-term debt$18.3M$21.3M$11.5M$10.8M$10.5M
Deferred revenue, non-current$680K$0.00$0.00$0.00$0.00
Total non-current liabilities$20.4M$23.6M$11.7M$10.8M$10.6M
Capital lease obligations$640K$3.68M$3.97M$3.31M$3.32M
Total liabilities$69.3M$45.2M$26.1M$25.8M$22.2M
Common stock$6.5M$6.43M$4.93M$4.44M$4.43M
Retained earnings-$-305.91M-$-217.74M-$-160.83M-$-118.21M-$-87.17M
Accumulated other comprehensive income (loss)$13.5M$10.2M$140K$180K$200K
Total equity$49.1M$113.3M$98M$120.3M$148.6M
Total investments$19.7M$51.4M$36.1M$77M$160K
Total debt$42.1M$22.7M$12.7M$11.9M$11.7M
Net debt$12.1M-$-11.53M-$-8.91M-$-6.01M-$-123.83M
Cash flow statement
20252024202320222021
Net income-$-90.05M-$-56.43M-$-44.66M-$-30.06M-$-24.64M
Depreciation and amortization$4.48M$2.72M$2.36M$1.93M$1.66M
Stock-based compensation$0.00$3.97M$2.61M$2.7M$1.27M
Change in working capital$5.37M$2.96M-$-3.49M$90K-$-1.14M
Accounts receivable-$-2.14M-$-750K-$-1.54M$10K-$-2.52M
Inventory$60K-$-1.4M-$-2.43M-$-540K-$-290K
Accounts payable$7.45M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-67.5M-$-49.23M-$-44.78M-$-28.76M-$-25.34M
Investments in property, plant and equipment-$-3.77M-$-1.17M-$-2.5M-$-890K-$-1.47M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$26.2M-$-16.32M$32M-$-89.95M-$-11.82M
Common stock issued$20.9M$69.7M$18.3M$260K$77.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$38.8M$77.4M$16.9M-$-980K$76.5M
Net change in cash-$-130K$12.6M$3.72M-$-117.62M$43.2M
Cash at end of period$30M$34.2M$21.6M$17.9M$135.5M
Operating cash flow-$-67.5M-$-49.23M-$-44.78M-$-28.76M-$-25.34M
Capital expenditure-$-800K-$-6.07M-$-10.96M-$-16.35M-$-11.82M
Free cash flow-$-68.3M-$-55.3M-$-55.74M-$-45.1M-$-37.15M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nyxoah S.A.

        Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

        CEO
        Olivier Taelman
        Employees
        154
        Beta
        0.96

        Explore

        Frequently asked questions

        What is the intrinsic value of Nyxoah S.A. (NYXH)?

        InvestorsCraft does not currently publish an intrinsic value for NYXH. How the IC value is calculated.

        Is NYXH undervalued?

        InvestorsCraft does not publish an undervaluation signal for NYXH at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.